

Appl. No. 09/461,774

AMENDMENTS TO THE CLAIMS

Please cancel claims 1-26 without prejudice or disclaimer of the subject matter set forth therein.

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of claims:

1-26. (Canceled)

27. (New) An isolated polypeptide comprising a polypeptide having an amino acid sequence of SEQ ID NO: 4, 6, 8 or 10, or having an amino acid sequence that is at least 70% identical to an amino acid sequence of SEQ ID NO: 4, 6, 8 or 10, wherein said polypeptide exhibits reactivity of from 5 to 52.5% with antisera obtained from subjects that have been infected by a *Mycobacterium* species and wherein said polypeptide exhibits a reactivity of 0% with sera obtained from subjects that have not been previously infected by a *Mycobacterium* species.

Appl. No. 09/461,774

28. (New) An isolated polypeptide comprising a polypeptide having an amino acid sequence of SEQ ID NO: 13, 15, 17, 19 or 21, wherein said polypeptide exhibits reactivity of from 5 to 52.5% with antisera obtained from subjects that have been infected by a *Mycobacterium* species and wherein said polypeptide exhibits a reactivity of 0% with sera obtained from subjects that have not been previously infected by a *Mycobacterium* species.

29. (New) An isolated polypeptide comprising a polypeptide having an amino acid sequence of SEQ ID NO:2, or having an amino acid sequence that is at least 70% identical to an amino acid sequence of SEQ ID NO: 2, wherein said polypeptide exhibits reactivity of from 35 to 55% with antisera obtained from subjects that have been infected by a *Mycobacterium* species and wherein said polypeptide exhibits a reactivity of 5 to 25% with sera obtained from subjects that have not been previously infected by a *Mycobacterium* species.

30. (New) An isolated polypeptide comprising a polypeptide having an amino acid sequence of SEQ ID NO: 11, wherein said polypeptide exhibits reactivity of from 35 to 55% with antisera obtained from subjects that have been infected by a *Mycobacterium*

Appl. No. 09/461,774

species and wherein said polypeptide exhibits a reactivity of 5 to 25% with sera obtained from subjects that have not been previously infected by a *Mycobacterium* species.

31. (New) A composition comprising at least two polypeptides having an amino acid sequence of SEQ ID NO: 4, 6, 8 or 10, or having an amino acid sequence that is at least 70% identical to an amino acid sequence of SEQ ID NO: 4, 6, 8 or 10, wherein said composition exhibits reactivity of more than 90% with antisera obtained from subjects that have been infected by a *Mycobacterium* species.

32. (New) A composition comprising at least two polypeptides comprising an amino acid sequence of SEQ ID NO: 13, 15, 17, 19 or 21, wherein said composition exhibits reactivity of at least 60% with antisera obtained from subjects that have been infected by a *Mycobacterium* species and wherein said composition exhibits a reactivity of 0 to 5% with sera obtained from subjects that have not been previously infected by a *Mycobacterium* species.

33. (New) The isolated polypeptide of claim 27 that has an amino acid sequence of SEQ ID NO: 4, 6, 8 or 10.

Appl. No. 09/461,774

34. (New) The isolated polypeptide of claim 28 that has an amino acid sequence of SEQ ID NO: 13, 15, 17, 19 or 21.

35. (New) The isolated polypeptide of claim 29 that has an amino acid sequence of SEQ ID NO: 11.

36. (New) The isolated polypeptide of claim 30 that has an amino acid sequence of SEQ ID NO: 2.

37. (New) The composition of claim 32, wherein said polypeptides consist essentially of the amino acid sequence of SEQ ID NO: 13, 15, 17, 19 or 21.

38. (New) The composition of claim 31, that comprises polypeptides having the amino acid sequence of SEQ ID NO: 4, 6, 8 and 10, or sequences that are 70% identical thereto.

39. (New) The composition of claim 31, that comprises polypeptides having the amino acid sequence of SEQ ID NO: 4, 6, 8 and 10.

Appl. No. 09/461,774

40. (New) The isolated polypeptide of claim 27, that is isolated from a *Mycobacterium* selected from the group consisting of *Mycobacterium tuberculosis*, *Mycobacterium avium*, *Mycobacterium microti*, *Mycobacterium leprae*, *Mycobacterium lepraemurium*, *Mycobacterium paratuberculosis*, *Mycobacterium ulcerans*, *Mycobacterium marinum*, *Mycobacterium smegmatis*, *Mycobacterium intracellulare*, *Mycobacterium xenopi*, *Mycobacterium chelonae*, *Mycobacterium fortuitum*, *Mycobacterium farcinogenes*, *Mycobacterium flavum*, *Mycobacterium haemophilum*, *Mycobacterium kansasii*, *Mycobacterium phlei*, *Mycobacterium scrofulaceum*, *Mycobacterium senegalense*, *Mycobacterium simiae*, *Mycobacterium thermoresistibile*, and *Mycobacterium xenopi*.

41. (New) The isolated polypeptide of claim 28, that is isolated from a *Mycobacterium* selected from the group consisting of the *Mycobacterium tuberculosis*, *Mycobacterium avium*, *Mycobacterium microti*, *Mycobacterium leprae*, *Mycobacterium lepraemurium*, *Mycobacterium paratuberculosis*, *Mycobacterium ulcerans*, *Mycobacterium marinum*, *Mycobacterium smegmatis*, *Mycobacterium intracellulare*, *Mycobacterium xenopi*, *Mycobacterium chelonae*, *Mycobacterium fortuitum*, *Mycobacterium farcinogenes*, *Mycobacterium flavum*, *Mycobacterium haemophilum*, *Mycobacterium kansasii*,

Appl. No. 09/461,774

*Mycobacterium phlei*, *Mycobacterium scrofulaceum*, *Mycobacterium senegalense*, *Mycobacterium simiae*, *Mycobacterium thermoresistibile*, and *Mycobacterium xenopi*.

42. (New) The composition of claim 31, wherein said polypeptides are isolated from at least one *Mycobacterium* wherein the species of *Mycobacterium* selected from *Mycobacterium tuberculosis*, *Mycobacterium avium*, *Mycobacterium microti*, *Mycobacterium leprae*, *Mycobacterium lepraemurium*, *Mycobacterium paratuberculosis*, *Mycobacterium ulcerans*, *Mycobacterium marinum*, *Mycobacterium smegmatis*, *Mycobacterium intracellulare*, *Mycobacterium xenopi*, *Mycobacterium chelonae*, *Mycobacterium fortuitum*, *Mycobacterium farcinogenes*, *Mycobacterium flavum*, *Mycobacterium haemophilum*, *Mycobacterium kansasii*, *Mycobacterium phlei*, *Mycobacterium scrofulaceum*, *Mycobacterium senegalense*, *Mycobacterium simiae*, *Mycobacterium thermoresistibile*, and *Mycobacterium xenopi*.

43. (New) The composition of claim 32, wherein said polypeptides are isolated from at least one *Mycobacterium* selected from the group consisting of *Mycobacterium tuberculosis*, *Mycobacterium avium*, *Mycobacterium microti*, *Mycobacterium leprae*, *Mycobacterium lepraemurium*, *Mycobacterium paratuberculosis*,

Appl. No. 09/461,774

*Mycobacterium ulcerans*, *Mycobacterium marinum*, *Mycobacterium smegmatis*, *Mycobacterium intracellulare*, *Mycobacterium xenopi*, *Mycobacterium chelonae*, *Mycobacterium fortuitum*, *Mycobacterium farcinogenes*, *Mycobacterium flavum*, *Mycobacterium haemophilum*, *Mycobacterium kansasii*, *Mycobacterium phlei*, *Mycobacterium scrofulaceum*, *Mycobacterium senegalense*, *Mycobacterium simiae*, *Mycobacterium thermoresistibile*, and *Mycobacterium xenopi*.

44. (New) The composition of claim 31, that further comprises the 38 kilodalton antigen of *M. tuberculosis*.

45. (New) The composition of claim 32, that further comprises the 38 kilodalton antigen of *M. tuberculosis*.

46. (New) The isolated polypeptide of claim 28, wherein the polypeptide has a molecular weight of from 5 to 100 kilodaltons.

47. (New) The isolated polypeptide of claim 28, wherein the polypeptide has a molecular weight of from 28 to 65 kilodaltons.